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A glycosaminoglycan mimetic peptide nanofiber
gel as an osteoinductive scaffold†
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Gullu Kiziltas Sendur,d,e Nuray Can,f Huseyin Ozkan,f Elif Ergul,a
Mustafa O. Guler*a and Ayse B. Tekinay*a
Biomineralization of the extracellular matrix (ECM) plays a crucial role in bone formation. Functional and
structural biomimetic native bone ECM components can therefore be used to change the fate of stem
cells and induce bone regeneration and mineralization. Glycosaminoglycan (GAG) mimetic peptide
nanofibers can interact with several growth factors. These nanostructures are capable of enhancing the
osteogenic activity and mineral deposition of osteoblastic cells, which is indicative of their potential appli-
cation in bone tissue regeneration. In this study, we investigated the potential of GAG-mimetic peptide
nanofibers to promote the osteogenic differentiation of rat mesenchymal stem cells (rMSCs) in vitro and
enhance the bone regeneration and biomineralization process in vivo in a rabbit tibial bone defect model.
Alkaline phosphatase (ALP) activity and Alizarin red staining results suggested that osteogenic differen-
tiation is enhanced when rMSCs are cultured on GAG-mimetic peptide nanofibers. Moreover, osteogenic
marker genes were shown to be upregulated in the presence of the peptide nanofiber system. Histo-
logical and micro-computed tomography (Micro-CT) observations of regenerated bone defects in rabbit
tibia bone also suggested that the injection of a GAG-mimetic nanofiber gel supports cortical bone de-
position by enhancing the secretion of an inorganic mineral matrix. The volume of the repaired cortical
bone was higher in GAG-PA gel injected animals. The overall results indicate that GAG-mimetic peptide
nanofibers can be utilized effectively as a new bioactive platform for bone regeneration.
1. Introduction
Bone tissue defects can occur as a result of trauma, organic
bone diseases, infectious diseases, and surgeries. The treat-
ment of bone defects is a major reconstructive challenge in
the field of orthopedics.1 While the gold standard of clinical
care is the autograft, the use of autografts, xenografts and allo-
grafts is limited due to their lack of availability, the risk of
infections, donor site morbidity, and the potential of trans-
plant rejection.2 These problems can be overcome by using
scaffolds made of synthetic or natural biomaterials promoting
the migration, proliferation, and differentiation of bone
cells.3,4 Advances in nanotechnology and tissue engineering
offer promising options for the regeneration and replacement
of damaged bone.5
Supramolecular peptide nanofiber systems are used as syn-
thetic scaffolds in regenerative medicine applications because
of their tailorable properties and ability to mimic ECM
proteins.6–9 Peptide nanofibers are attractive for regeneration
of bone defects because bone is a composite consisting of a
protein based soft template (i.e., a mixture of collagen, non-
collagenous proteins (laminin, fibronectin, vitronectin) and
water) and hard inorganic components (hydroxyapatite (HA),
Ca10(PO4)6(OH)2).
10,11 70% of the bone inorganic matrix is
composed of HA crystals, which are typically 30–50 nm long
and 1.5–4 nm thick.12 Other protein components in the bone
ECM are also in the nanometer scale, and the adhesion, pro-
liferation and differentiation of resident mesenchymal stem
cells (MSCs), osteoblasts, osteoclasts and fibroblasts are
known to be affected by this self-assembled nanostructured
ECM. Bone tissue contains less than 1% glycosaminoglycans
(GAGs)13,14 consisting of about 90% chondroitin-4-sulfate and
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small amounts of hyaluronic acid, chondroitin-6-sulfate, and
dermatan sulfate.15 GAGs have significant regulatory roles in
the development and regeneration of bone tissue. They exhibit
complex effects on the behavior of bone cells at all stages of
their differentiation, and facilitate the attraction and adhesion
of precursor cells, their subsequent differentiation and their
interactions with other proteins.16 Sulfated GAGs, which are
rich in negatively charged sulfate groups, are important for
bone formation due to their ability to interact with growth
factors such as FGF, BMPs, TGF-β1 and IGF-II, which are
involved in regulating the osteoblastic cells. Sulfated GAGs
work by binding to the positively charged amino groups of
various proteins and growth factors, thus increasing their local
availability.17,18
We have previously shown that GAG mimetic peptide nano-
fibers can interact with several growth factors, including vascu-
lar endothelial growth factor (VEGF), fibroblast growth factor-2
(FGF-2) and hepatocyte growth factor (HGF).19 In addition, we
have recently demonstrated that glycosaminoglycan mimetic
peptide nanofibers are able to interact with bone morpho-
genetic protein-2 (BMP-2), which is a critical growth factor for
osteogenic activity.20 The GAG mimicking ability of the
peptide nanofibers and their interaction with BMP-2 promoted
osteogenic activity and mineralization by osteoblastic cells.20
Since MSCs have self-renewing capabilities and multi-lineage
differentiation potential,21 there is currently a strong need for
the fabrication of a biomaterial scaffold that is able to support
and direct these cells towards the osteoblastic lineage. In this
study, we show that GAG-mimetic peptide nanofibers can
provide a suitable microenvironment for the osteogenic differ-
entiation of rat mesenchymal stem cells (rMSCs). We also
demonstrate that these nanofibers enhance bone regeneration
and biomineralization in a rabbit tibial bone defect model.
2. Materials & methods
2.1. Materials
4-(2′,4′-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-
norleucyl-MBHA resin (Rink amide MBHA resin), Fmoc-
Asp(OtBu)-Wang resin, all protected amino acids, lauric acid,
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluoro-
phosphate (HBTU), and diisopropylethylamine (DIEA) were
purchased from Novabiochem, ABCR, or Sigma-Aldrich.
Calcein-AM and other cell culture materials were purchased
from Invitrogen. All other chemicals and materials used in
this study were purchased from Thermo Scientific or Sigma-
Aldrich.
2.2. Synthesis of peptide amphiphile (PA) molecules
The Fmoc solid phase peptide synthesis method was used to
synthesize Lauryl-Val-Val-Ala-Gly-Lys-Am (K-PA), Lauryl-Val-Val-
Ala-Gly-Glu (E-PA), and Lauryl-Val-Val-Ala-Gly-Glu-Gly-Asp (Lys-
p-sulfobenzoate)-Ser-Am (GAG-PA). Rink amide MBHA resin
(Novabiochem) was used as the solid support for K-PA and
GAG-PA, while Fmoc-Glu(OtBu)-Wang resin (100–200 mesh)
served as the solid support for E-PA. Amino acid couplings
were carried out with 2 molar equivalents of a Fmoc protected
amino acid, 1.95 molar equivalents of HBTU, and 3 molar
equivalents of DIEA for 3 h. The removal of the Fmoc protect-
ing group on the Nα-amino group of the peptide was per-
formed with addition of 20% piperidine in
dimethylformamide (DMF) solution for 20 min. In order to
block the remaining free amine groups after amino acid coup-
ling, 10% acetic anhydride in DMF solution was used. The
resin was washed by using DMF and dichloromethane (DCM)
after each step. To synthesize GAG-PA, a p-sulfobenzoic acid
residue was added to the side-chain of lysine. A lysine residue
with a 4-methyltrityl (Mtt) side-chain protecting group was
used for selective deprotection of amine groups. In order to
remove Mtt, the resin was shaken for 5 min with trifluoroacetic
acid (TFA) : triisopropylsilane (TIS) : H2O : DCM at a ratio of
5 : 2.5 : 2.5 : 90. The cleavage of PAs and protecting groups from
the resin was carried out with a mixture of TFA : TIS : H2O at a
ratio of 95 : 2.5 : 2.5 for 2.5 h. Excess TFA was removed by
rotary evaporation, and PAs were precipitated using ice-cold
diethyl ether at −20 °C overnight. The precipitate was then col-
lected by centrifugation, dissolved in ultrapure water and
frozen at −80 °C overnight. The frozen samples were lyophi-
lized for 4 days. The identity and purity of peptide amphi-
philes were assessed by LC-MS (Agilent 6530-1200 Q-TOF)
analysis. Mass spectra were obtained with an Agilent LC-MS
equipped with an Agilent 6530 Q-TOF with an ESI source and
Zorbax Extend-C18 2.1 mm × 50 mm column for basic con-
ditions and a Zorbax SB-C8 4.6 mm × 100 mm column for
acidic conditions. A gradient of water (0.1% formic acid or
0.1% NH4OH) and acetonitrile (0.1% formic acid or 0.1%
NH4OH) was used as the mobile phase. To purify the peptides,
an Agilent preparative reverse-phase HPLC system equipped
with a Zorbax Extend-C18 21.2 mm × 150 mm column was
used for basic conditions, and a Zorbax SB-C8 21.2 mm ×
150 mm column was used for acidic conditions. A gradient of
water (0.1% TFA or 0.1% NH4OH) and acetonitrile (0.1% TFA
or 0.1% NH4OH) was used as the mobile phase. Positively
charged PAs were treated with 0.1 M HCl solution and lyophi-
lized to remove residual TFA.
2.3 Scanning electron microscope (SEM) imaging of PA
nanofiber networks
SEM was used to observe the nanofiber networks formed by
PAs. Samples were prepared on silicon wafer by mixing oppo-
sitely charged PA solutions (10 mM) in a final volume of 60 µL.
Briefly, GAG-PA and E-PA were mixed with K-PA at 1 : 3 and
1 : 2 ratios to stabilize all net charges. 15 min after gelation
occurred, the samples were dehydrated by sequential treat-
ment with 20%, 40%, 60%, 80% and 100% v/v ethanol.
After the ethanol gradient exchange, critical point drying was
performed by using an Autosamdri-815B critical point dryer
(Tousimis). The dried samples were coated with 4 nm Au–Pd
before imaging and images were taken by using a FEI Quanta
200 FEG scanning electron microscope at high vacuum mode
with 5 keV beam energy.
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2.4 Circular dichroism (CD)
CD samples were prepared by using 3 × 10−2 mM GAG-PA/
9 × 10−2 mM K-PA and 3 × 10−2 mM E-PA/6 × 10−2 mM K-PA
mixtures, respectively. A JASCO J815 CD spectrometer was used
at room temperature. The CD spectra of peptide solutions were
recorded in a range of 300 nm to 190 nm, with a data interval
and data pitch of 0.1 nm, and a scanning speed of 100
nm min−1, and all measurements representing three accumu-
lations. Digital integration time was selected as 1 s, bandwidth
as 1 nm, and the sensitivity was standard.
2.5 Fourier transform infrared (FT-IR) spectroscopy
FT-IR spectroscopy was used to obtain information about
the secondary structures of PAs. Briefly, 10 mM gels formed
on Petri dishes were frozen in liquid nitrogen and kept at
−80 °C overnight. Following the freeze drying process, the
dried samples were used to form pellets with KBr (100 mg KBr
per 1 mg dried sample) and absorbance analysis was
performed with a Bruker Vertex 70 FT-IR spectrometer in the
4000–400 cm−1 range.
2.6 Cell culture and maintenance
The rMSCs (Invitrogen, passage number 7) were used in all
cell culture experiments, including viability, calcium de-
position and gene expression analyses. Cells were cultured in
75 cm2 flasks at a density of 3 × 103 cells per cm2 at 37 °C in a
humidified incubator and supplied with 5% CO2. The rMSCs
were maintained in DMEM (low glucose) with L-glutamine sup-
plemented with 10% fetal bovine serum (FBS) and 1% penicil-
lin/streptomycin. All cell experiments were carried out after
the cells reached 90% confluency. The culture medium was
changed every 3–4 days. Cells were seeded under the same con-
ditions used for their maintenance. For mineralization experi-
ment, gene expression analysis, actin staining and SEM
imaging of cells the seeded cell medium was replaced with
osteogenic medium (DMEM with 10% FBS supplemented with
10 mM β-glycerophosphate, 50 µg mL−1 ascorbic acid and
10 nM dexamethasone) after reaching confluency.
2.7 Tissue culture plate coating
Tissue culture plate (TCP) surfaces were coated with peptides
at a concentration of 1 mM. To neutralize charges, GAG-PA
and E-PA were mixed with K-PA at 1 : 3 and 1 : 2 volume ratios,
respectively. After coating, the plates were placed in a fume
hood overnight for drying, and sterilized with UV light for 1 h
prior to cell culture experiments.
2.8 Viability assay
The viability of rMSCs incubated on PA coated and uncoated
TCP was studied by the Live/Dead assay (Invitrogen). Briefly,
the cells were seeded on PA-coated and uncoated 96-well
tissue culture plates at a density of 5 × 103 cells per well. After
24, 48, and 72 h of incubation, the cell medium was discarded;
the cells were washed with phosphate buffered saline (PBS)
and then incubated with 2 μM calcein-AM and 2 μM EthD-1 in
PBS for 30 min at room temperature. After incubation, images
were taken at three random points per well with a fluorescent
microscope (Zeiss, Axio Scope A1) at 10× magnification. All
samples were analyzed in triplicate. Live and dead cells were
counted by using Image J and the number of live cells was cal-
culated for each sample.
2.9 Actin staining of rMSCs on PA nanofiber coated surfaces
Glass coverslips were coated with PAs, and the cells were
seeded on top of the coated and uncoated surfaces at a density
of 3 × 103 cells per cm2. Before phalloidin/TO-PRO-3 staining,
the cells were fixed with 4% formaldehyde for 15 min and per-
meabilized with 0.1% Triton-X for 10 min at room tempera-
ture. The samples were incubated with 3% (w/v) bovine serum
albumin (BSA)/PBS for 30 min for blocking. Actin filaments of
the cells were initially stained with FITC-conjugated phalloidin
(Thermo Fisher) in 3% (w/v) BSA/PBS for 20 min. After serial
washing steps, the samples were stained with TO-PRO-3
(Thermo Fisher) in PBS for 20 min for the visualization of
nuclei. Coverslips were mounted with the Prolong Gold Anti-
fade Reagent (Invitrogen). The cytoskeletal organization of the
cells was observed using a Zeiss LSM 510 confocal microscope.
Images were taken at 63× magnification.
2.10 SEM imaging of rMSCs on PA nanofiber coated surfaces
The morphology and spreading of MSCs were examined by
SEM imaging by using an ETD detector at high vacuum mode
at 5 keV beam energy. For this purpose, glass coverslips were
coated with PAs, and the cells were seeded on top of the coated
and uncoated surfaces at a density of 3 × 103 cells per cm2. 3
and 14 days after incubation, the cells were rinsed with PBS
and fixed with 2% glutaraldehyde/PBS and 1 wt% OsO4 for 1 h
each, respectively. The fixed cells were washed with water, and
then dehydrated sequentially in 20%, 40%, 60%, 80%, and
100% ethanol. The samples were critical point dried with Auto-
samdri-815B Tousimis and coated with 5 nm Au–Pd before
imaging.
2.11 Alkaline phosphatase (ALP) activity assay
In order to measure the ALP activity of rMSCs, degradation of
p-nitrophenol due to endogenous ALP activity was quantified
after 7 and 14 days of culture in osteogenic medium. Briefly,
the cells were seeded on PA nanofiber-coated and uncoated
TCP surfaces at a density of 3 × 103 cells per cm2 and the cell
medium was replaced with osteogenic medium after the cells
reached confluency. The cells were rinsed with PBS at pre-
determined time points. An M-PER protein extraction kit
(Thermo) with a 5% protease inhibitor solution was used to
extract proteins. Supernatants containing the protein fraction
were removed after centrifugation at 14 000g for 10 min. The
Pierce BCA protein assay (Thermo) was performed to quantify
the amount of protein obtained from the cells as described in
the manufacturer’s protocol. To measure ALP activity, 50 µL of
the protein sample was incubated with 150 µL of p-nitrophenol
phosphate substrate in 96-well plates for 30 min on a shaker.
Serial dilutions of p-nitrophenol in 0.25 M NaOH solution
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were used as standards. Finally, the optical density of the
samples was determined at 405 nm using a Spectramax
M5 microplate reader and the ALP results were normalized to
the total amount of protein at each time point tested.
2.12 Detection of mineralization by Alizarin red staining
Calcium deposition on the surface of hydrogels was
measured on days 14 and 28 using Alizarin red staining.
Briefly, rMSCs were seeded on PA coated and uncoated TCPs
at a density of 3 × 103 cells per cm2 in DMEM medium con-
taining 10% FBS and 1% penicillin–streptomycin. The cells
were cultured in this medium until they reached confluency,
and the medium was then replaced with fresh osteogenic
medium. This medium was replenished every 3–4 days over
the course of experiments. At predetermined time intervals,
the cells were fixed with ice-cold ethanol for 1 h and stained
with 40 mM Alizarin-red S for 30 min on a shaker. Afterwards
the samples were washed 4–5 times with double distilled
water to get rid of non-specific Alizarin-red binding. Calcium
nodules were imaged in PBS under light microscopy. In order
to quantify deposited calcium, PBS was discarded and the
samples were incubated in 10% cetylpyridinium chloride for
30 min at room temperature. At the end of the incubation
period, the solution was transferred to 96-well plates and
absorbance measurements were performed at 562 nm.
2.13 Gene expression analysis
For gene expression studies, the surfaces of TCP were coated
with each PA mixture. rMSCs were seeded at a density of
3 × 103 cells per cm2. After the cells had reached confluency,
their media were replaced with osteogenic medium. The gene
expression profiles for osteogenic differentiation (Runx2,
collagen I, and osteopontin) were evaluated by quantitative
RT-PCR (qRT-PCR) analysis. RNA isolation from rMSCs seeded
on the PA nanofibers and bare surfaces was performed by
using TRIzol (Invitrogen) according to the manufacturer’s
instructions after 7 and 14 days of incubation. The yield and
purity of the extracted RNA were assessed by using Nanodrop
2000 (Thermo Scientific). The samples were diluted to a con-
centration of 100 ng μL−1 prior to their use. Primers for PCR
amplification of Runx2, collagen I, osteopontin and GAPDH
are shown in Table 1. cDNA synthesis from RNA and qRT-PCR
was performed using the SuperScript III Platinum SYBR Green
One-Step qRT-PCR kit according to the manufacturer’s instruc-
tions. mRNA levels were calculated and normalized to GAPDH
according to the comparative Ct method for each target gene.
2.14 In vivo experiments
In vivo experiments were carried out with 4 young adult New
Zealand rabbits per group weighing between 2.8 and 3.2 kg.
All animal studies were approved by Gülhane Military Medical
Academy Animal Studies Ethical Committee, and all experi-
ments were conducted in accordance with the NIH Guide for
Care and Use of Laboratory Animals.
2.14.1. Surgical procedure. GAG-PA and K-PA molecules
were dissolved in ddH2O at a concentration of 10 mM and
sterilized under UV light for 1 h. Rabbits were anesthetized with
an intramuscular injection (IM) of 35 mg kg−1 of ketamine
hydrochloride and 5 mg kg−1 of xylazine hydrochloride. The
region of operation was shaved and aseptically prepared for
operation. Under general anesthesia, a proximal tibial meta-
physeal surgical defect (2 mm in diameter) was made on the
right tibia of animals by using a surgical drill and PA solutions
were injected into the tibial defects. Defect entrances were
sutured (Vicryl 4–0 absorbable suture) after PA injections. In
the physiological saline sham group, right tibial defects were
formed in a similar fashion and sutured following the injec-
tion of physiological saline. IM antibiotics were given to each
rabbit for 3 days following the operation. All the tibias were
examined regularly clinically for any sign of inflammation or
infection for the duration of the study. GAG-PA/K-PA (n = 4)
and physiological saline (n = 4) injected tibiae were surgically
removed after 4 weeks for bone morphometric analysis and
histology characterization. All rabbits were sacrificed with an
intravenous injection of 100 mg kg−1 sodium pentobarbital.
Tibiae were fixed with 10% formalin for 48 h and stored in
70% EtOH for Micro-CT measurements.
2.14.2 Micro computed tomography (Micro-CT) analysis.
Micro-CT scans were performed to quantify new bone for-
mation and mineral density within the defect. The distal meta-
physeal regions of all tibiae were scanned at 81 kV and 124 µA
using a Skyscan1172 Micro-CT scanner. Specimens were
scanned using a 0.25 mm aluminium-copper filter and under
305 ms exposure time. For each specimen, a series of 660 pro-
jection images were obtained with a rotation step of 0.7 three-
frame averages and a total rotation of 360°. Each scan was pre-
ceded by flat field correction for a specific zoom and image
format. A stack of two-dimensional X-ray shadow projections
was reconstructed using NRecon software v1.6.9.4 (Skyscan)
and morphometrically analyzed using CTAn software v1.14.4.1
(Skyscan). During reconstruction, dynamic image range, post-
alignment value, beam hardening and ring-artifact reduction
were optimized for each experimental set. The defect region
was manually identified in each bone and defined as the
general volume of interest (VOI).
2.14.3 Histological analysis. For histological investigation,
tibiae samples were decalcified with 14% EDTA solution
and then embedded in paraffin. Tissues were sectioned
with a Leica microtome at 5 µm thickness. Sections were
Table 1 Primers used for qRT-PCR expression analysis










This journal is © The Royal Society of Chemistry 2016 Biomater. Sci., 2016, 4, 1328–1339 | 1331
View Article Online
deparaffinized in xylene and rehydrated in serial ethanol solu-
tions for hematoxylin and eosin (H&E) staining. Slides were
assessed at 5× objective magnification for area analysis by
using Image-J software. A 1 mm × 2 mm sized area including
the defect site as the centre is drawn. Quantification was
carried out by measuring the pink area percentage in the
defined site of the bone defect area for every sample. For
Masson’s trichrome staining, paraffin embedded slides were
fixed in Bouin’s solution. After incubation in Weigert’s iron
hematoxylin solution, the slides were stained with Biebrich
Scarlet-Acid Fuchsin and aniline blue and dehydrated in
ethanol and xylene. The samples were washed extensively
between each staining. The collagen fibers were stained blue
and the nuclei were stained black under this staining protocol.
For Alcian blue staining, sections were stained for 30 min with
Alcian blue solution (1 g of Alcian blue 8GX (Sigma, UK) dis-
solved in 3% glacial acetic acid (Sigma, UK)), washed in
running tap water for 2 min and counterstained with nuclear
fast red stain (Sigma, UK) for 5 min. Finally, the slides were
washed for 1 min in running tap water. All sections were
imaged under microscopy.
2.15 Statistical analysis
All quantitative values are presented as mean ± SEM (standard
error of mean), and all experiments were performed with at
least three replicates. Two-way analysis of variance (ANOVA)
was used for the statistical analysis of viability tests, quantifi-
cation of mineral deposition and gene expression studies.
Quantification of cortical bone formation results was analyzed
using the Mann–Whitney U-test. A p value of less than 0.05
was considered statistically significant. All statistical tests were
performed using Graph-pad Prism v5.0.
3. Results
3.1 Characterization of peptide amphiphile (PA) molecules
and self-assembled PA nanofibers
In this study, glycosaminoglycan-mimetic and control peptide
amphiphile (PA) molecules were synthesized using the solid
phase peptide synthesis method. GAG-PA (Lauryl-VVAGEGD(K-
p-sulfobenzoate)S)-Am) was used to mimic sulfated glycosami-
noglycans (GAGs) by presenting functional groups such as sul-
fonate, hydroxyl and carboxylate moieties, while E-PA (Lauryl-
VVAGE) was used to present carboxylate groups and had no
sulfonate groups.20 K-PA, a positively charged molecule was
used in order to induce nanofiber formation together with
negatively charged PAs through electrostatic interactions
(Fig. 1A). GAG-PA and E-PA molecules form nanofibers
through self-assembly when mixed with K-PA. All PA molecules
were characterized by liquid chromatography-mass spec-
trometry (LC-MS) and purified by preparative HPLC (Fig. S1–
S3†). For charge neutralization, GAG-PA was mixed with
K-PA at a 1 : 3 ratio to form GAG-PA/K-PA nanofibers, while
E-PA and K-PA were mixed at a 1 : 2 ratio to form E-PA/K-PA
nanofibers. Porous nanofiber networks were formed upon
mixing oppositely charged PA molecules, as demonstrated
by SEM images (Fig. 1C). CD spectra were acquired to
explore the secondary structures of self-assembled PA net-
works, and suggest that the β-sheet structure with a chiral
absorbance maximum at around 200 nm and minimum at
around 220 nm, is the predominant secondary structure for
both GAG-mimetic nanofibers and control nanofibers
(Fig. 1B). The FT-IR spectra of all PAs exhibit amide I, amide II
and amide A bands. The amide I band is uniquely useful
for analysis of protein secondary structural composition
and conformational changes.22 The bands in the regions of
Fig. 1 Design of peptide amphiphile molecules (PA). (A) Chemical structures of molecules. (B) CD measurements of the PA samples, demonstrating
a predominance of β-sheets in the PA nanofibers. (C) SEM images show the nanofibrous network.
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1640–1620 cm−1 and 1695–1690 cm−1 have been assigned to
β-sheets.23,24 In our study, all peptide nanofibers have amide I
peaks located between the 1630–1640 cm−1 region, indicating
β-sheet organization and validating our CD results (Fig. S4†).
3.2 Cell behavior and viability on PA nanofibers
The effect of GAG-mimetic peptide nanofibers on the viability
of rMSCs was tested by calcein AM staining at varying time
points (24, 48 and 72 h). The rMSCs were viable on all surfaces
over the three days period. We did not observe any significant
difference in the viability of cells on different peptide nano-
fiber scaffolds and bare glass surfaces at varying time points
(Fig. S5 and S6†). These results showed that peptide nano-
fibers provide a biocompatible environment.
SEM imaging and actin staining revealed that rMSCs had
spread and showed the characteristic fibroblast-like phenotype of
MSCs (i.e. a spindle-like morphology) after 3 days of incubation
on PA nanofibers25 (Fig. 2). Phalloidin staining showed that the
cells adhere on PA nanofibers and form cytoskeletal attach-
ments. From day 7 onward, the cells on GAG-PA/K-PA nanofibers
were found to cluster together and form bone like nodules,
which is one of the indicators of osteogenic differentiation26
(Fig. S7†). In contrast to our GAG-PA/K-PA observations, no clus-
tering or nodule formation was present on E-PA/K-PA or TCP.
3.3 Alkaline phosphatase activity and mineralization on
bioactive peptide nanofibers
Osteoblasts are the cells responsible for secreting organic and
mineral matrices during new bone formation in vivo. MSCs
express characteristic markers during their differentiation
into the osteoblastic lineage, which can be quantified to
determine the extent of the differentiation process. The osteo-
genic differentiation of MSCs occurs in three stages in vitro.27
A peak in the number of cells is seen in the first stage (days
one to four). This is followed by early cell differentiation from
days 5 to 14, which involves the transcription and protein
expression of ALP, an enzyme that promotes mineralization
by providing inorganic phosphate.27–29 Therefore, we tested
the ALP activity of rMSCs cultured on GAG-PA/K-PA,
E-PA/K-PA and TCP surfaces after 7 and 14 days of incubation
in osteogenic medium. Maximum ALP activity was observed
on day 7 for GAG-PA/K-PA, and was found to have decreased
at day 14 (Fig. 3A). ALP activity starts to decline after this
stage, and the final phase of osteogenic differentiation com-
prises the deposition of calcium and phosphate from days
15 to 28.27,30 These calcium deposits can specifically be
stained using Alizarin red S, which chelates Ca2+ and is a
commonly used dye for the evaluation of bone mineraliz-
ation.30,31 Cells cultured on GAG-mimetic peptide nanofibers
in the presence of osteogenic supplements showed matrix
mineralization with intense Alizarin red staining (Fig. 3B and
C), in contrast to control cultures, which stained negatively
for Alizarin red.
3.4 Gene expression profiles of osteogenic markers
MSCs cultured in osteogenic media express markers also
known to be expressed by bone-forming osteoblasts.32 To
understand whether the GAG-mimetic peptide nanofiber
systems were able to direct the differentiation of rMSCs
towards the osteogenic lineage, the gene expression profiles of
cells cultured on peptide nanofiber network coated and bare
surfaces were analyzed and quantified. Expressions of the
osteogenic markers Runt-related transcription factor 2
(Runx2), type I collagen (collagen I) and osteopontin were
examined at the mRNA level on days 7 and 14 (Fig. 5). Runx2
is often referred to as the master switch of osteogenic differen-
tiation33 and its expression is usually analyzed during the
early phases of osteogenic differentiation. The expression of
Runx2 was upregulated by ∼1 and 1.5 fold, when rMSCs were
cultured on GAG-PA/K-PA compared to the cells on TCP sur-
faces on days 7 and 14, respectively. This value was also upre-
gulated by ∼1.3 and 2.5 fold compared to the cells on
E-PA/K-PA surfaces on days 7 and 14, respectively. The major
organic component of bone ECM is type I collagen, which is
secreted at an early stage of osteogenic differentiation, provid-
ing a scaffold for mineral deposition.34,35 Osteopontin is a
highly phosphorylated sialoprotein that is a prominent com-
ponent of the mineralized extracellular matrices of bones.36
Osteopontin expression was tested as a third osteogenic
marker and found to be upregulated by ∼1.5 and 2.8 fold for
rMSCs cultured on GAG-PA/K-PA compared to the cells on
TCP surfaces on days 7 and 14, respectively. This value was
also significantly upregulated by ∼2.3 fold compared to the
cells on E-PA/K-PA surfaces on day 7, and 1.5 fold on day 14.
Studies on the temporal expression of osteopontin during
Fig. 2 Morphology of rMSCs on PA nanofibers and TCP after 3 days of
incubation. Actin filaments stained with phalloidin (green) and nuclei
stained with TO-PRO-3 (blue) (A, C, and E). Scale bars are 20 μm. SEM
images of rMSCs on PA nanofibers and TCP (B, D, and F). Scale bars are
5 μm.
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the formation of bone in vitro and during the formation of
intramembranous and endochondral bone in vivo have
revealed a biphasic pattern in which osteopontin is produced
early in the differentiation of bone cells, with higher levels
expressed after mineralization has been initiated.36 More
differences observed on day 7 are therefore consistent with
previous studies. Mineralization can be initiated by the matrix
vesicle budding from the plasma membrane of osteoblasts,
which creates an environment suitable for the crystallization
of calcium and phosphate.37 Collagen can act as a template
for this process, and may also initiate and propagate mineral-
ization independent of the matrix vesicles.38 In addition, this
protein plays an important role in cell adhesion, proliferation,
and differentiation into the osteoblast phenotype. Collagen I
expression was significantly upregulated in the cells when
they were cultured on GAG-PA/K-PA compared to TCP, exhibit-
ing an enhancement of ∼1.3 and 3.3 fold on days 7 and 14.
This value was also upregulated by ∼2 and 10 fold compared
to the cells on E-PA/K-PA surfaces on days 7 and 14,
respectively.
3.5 In vivo bone regeneration model
An ideal bone substitute should be tested both in vitro and
in vivo prior to its evaluation in human beings to ensure its safety
and effectiveness.39 Tibial bone defect models are commonly
used to study regeneration in long bones.40,41 Rabbits are one
of the most commonly used animal models, and rank first
among all animals used for musculoskeletal research.42 After
testing our system in vitro, we checked the regeneration ability
of GAG-mimetic peptide nanofibers using a rabbit tibial defect
model. The non-bioactive (E-PA/K-PA) peptide nanofiber group
did not enhance differentiation into the osteogenic lineage.
Fig. 3 Differentiation analyses of rMSCs on bioactive peptide nanofibers. (A) Impact of GAG-mimetic peptide nanofibers on alkaline phosphatase
activity on days 7 and 14, *p < 0.05, ***p < 0.001. (B) Quantification of relative calcium deposition on peptide nanofibers and TCP on days 14 and 28,
***p < 0.001. (C) Biomineralization on peptide nanofibers and TCP on days 14 and 28 as demonstrated by Alizarin red staining. Scale bars are
100 μm.
Fig. 4 SEM images of rMSCs cultured on GAG-PA/K-PA, E-PA/K-PA gels, and TCP at 14 days after cell seeding. Scale bars are 40 μm.
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Therefore, the E-PA/K-PA group was not utilized in in vivo
studies.
3.5.1 Quantification of bone formation by Micro-CT. We
reconstructed three-dimensional images from Micro-CT data
of the GAG-PA gel treated group and the physiological saline
treated group for analyzing new bone formation (Fig. 7). The
reconstructed 3-dimensional images showed that the GAG-PA
gel treated group had more abundant cortical bone formation
than the physiological saline treated group. In addition, the
bone volume to total volume ratio (BV/TV), which indicates the
portion of mineralized tissue, was assessed. In fact, the
GAG-PA gel treated group has a statistically higher BV/TV than
the physiological saline treated group (Fig. 6A). The BV/TV (%)
value for the gel treated group was ∼53%, while it was ∼19%
for the physiological saline treated group (Fig. 6A). Bone
mineral density (BMD) can be defined as the volumetric
density of calcium hydroxyapatite in a biological tissue in
terms of g cm−3. In this study, Micro-CT quantifications have
demonstrated that the animals receiving the GAG-PA gel treat-
ment showed significantly higher BMD scores (∼1.03 g cm−3),
representing a 2.5 fold increase in the BMD score compared to
the physiological saline treated group (∼0.41 g cm−3) (Fig. 6B).
3.5.2 Histological evaluation of regenerated bone. Histo-
logical analyses were performed to investigate the regeneration
process in tibial bone defects following GAG-PA gel and saline
(control) treatment. The morphology of the damaged area and
the formation of new bone ECM after surgery were examined
by H&E staining. During bone healing, the soft, avascular carti-
laginous callus is infiltrated by blood vessels and converted
into woven bone, which is then gradually replaced by mature
cortical bone.43 In our study, physiological saline-treated
defects mostly exhibited woven bone formation with vascular
Fig. 5 Gene expression analysis of Runx2, collagen I, and osteopontin on days 7 and 14. The expression level of each gene was normalized against
TCP and GAPDH was used as the internal control, *p < 0.05, **p < 0.01.
Fig. 6 Newly formed cortical bone analysis at the defect site of rabbit tibia after 4 weeks of GAG-PA gel treatment. (A) BV/TV (%). (B) BMD of
cortical bone, *p < 0.05.
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invasion, with a minor presence of lamellar bone formation
(Fig. S8†). On the other hand, GAG-PA gel treatment largely
enhanced the healing process resulting in the formation of
cortical bone (Fig. 6A and S8†). Bone regeneration was also
quantitatively evaluated by determining the percentage of
regenerated area with respect to the original defect area using
H&E results (Fig. 8G). On average, 56% of the initial defect was
repaired in GAG-PA gel treated tibia, while this value was 37%
for physiological saline. The measurements correlated with
Micro-CT analysis which showed 54% new bone formation for
the GAG-PA gel treated group on average. Masson’s trichrome
staining studies showed that collagen deposition (as indicated
by blue color) was prominent in tibial bone defects following
both saline and GAG-PA gel treatments (Fig. 8B–E), indicating
that the bone matrix is actively synthesized during the treat-
ment period. In GAG-PA gel treated defects, the newly formed
bone turned to a red color which shows that the new bone had
undergone maturation.40 Both defects also stained positive for
Alcian blue (blue color, Fig. 8C–F); however, Alcian blue stain-
ing was especially abundant in physiological saline treated
defects (Fig. 8F), suggesting an association between bone
regeneration and cartilage formation.40
Fig. 8 Histological evaluation of a tibial defect model after 4 weeks of GAG-PA gel treatment. Tissue sections of GAG-PA gel treated and physio-
logical saline sham groups were stained with H&E (A, D) (black lines show regenerated area). Deposition of the bone matrix was confirmed by posi-
tive staining of collagen with Masson’s trichrome staining (B, E). Endochondral ossification was observed by Alcian blue staining (C, F). Scale bars are
200 µm. Regenerated bone areas were quantified through the histological evaluation of H&E results (G), *p < 0.05.
Fig. 7 Representative Micro-CT images after 4 weeks of GAG-PA gel
treatment. (A) Three-dimensional reconstruction images of one voxel of
interest showing newly formed bone (grey color: the newly formed bone,
black color: total defect volume). (B) NRecon images showing a defect site.
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4. Discussion
Scaffolds that mimic the structure and function of ECM com-
ponents are able to improve cellular responses and show great
promise in tissue engineering applications. Heparan sulfate
(HS) is an important component of the bone ECM and assists
in bone formation by providing structural support and control-
ling the presentation of growth factors to cell surface recep-
tors.44,45 This ability of HS makes it an attractive therapeutic
agent for the treatment of bone defects, as HS is able to bind
and present growth factors such as FGF and BMP that play
critical roles in defect healing following fracture haematoma.
However, the in vivo delivery of HS is not a well-controlled
process. Consequently, we designed a synthetic scaffold, which
mimics the structural and biochemical properties of sulfated
glycosaminoglycans, and tested the efficiency of this system to
assist in bone regeneration using an in vivo tibial bone defect
model. The ability of self-assembled PA nanofibers to mimic
natural ECM renders them attractive for regenerative medicine
applications. PA nanofibers can be modified to meet the needs
of a broad variety of tissues through the optimization of their
functional peptide sequences. The PA molecules self-assemble
into 1D nanostructures consisting of a fatty acid or a hydro-
phobic moiety linked to a hydrophilic peptide sequence. High-
aspect-ratio cylindrical nanofibers are observed when the
peptide sequence includes amino acids with high β-sheet
propensity. Screening of charged groups (by pH or ionic
strength changes) results in a self-supporting gel formation,
which is formed by a network of nanofibers with an enmeshed
solvent.46 Hydrophobic collapse of alkyl groups and β-sheet
formation between peptide molecules result in the formation
of nanofibers in aqueous solutions, and short bioactive amino
acid sequences can be presented at high densities on the
surface of these nanofibers. Previously, we showed that
heparin mimetic peptide nanofibers are able to bind BMP-2
better than E-PA/K-PA nanofibers, which may promote bone
repair by increasing the local concentration of growth factors
secreted by osteoblasts.20 A considerable difference was
observed between the ALP activity of Saos-2 cells on
GAG-PA/K-PA and E-PA/K-PA nanofibers, which is possibly due
to the differentiative capacity of bioactive and non-bioactive PA
networks to bind and present growth factors such as BMP-2.
During ossification, MSCs proliferate while staying in close
proximity, which results in the formation of dense cellular
aggregations or primary bone nodules. The MSCs in these
nodules start to differentiate into osteoprogenitor cells and
finally osteoblasts.26 MSCs on GAG-PA/K-PA gels start to
aggregate from day 7 onwards and form bone nodules at day
14, as shown by phalloidin staining and SEM imaging
(Fig. S7† and Fig. 4). MSCs have no extracellular calcium
deposits, while differentiated osteoblasts are known to exten-
sively deposit calcium crystals under both in vivo and in vitro
conditions. Calcium deposits are therefore an indication of
MSC towards osteoblast differentiation and in vitro bone for-
mation. In this study, the cells cultured on GAG-mimetic
peptide nanofibers in the presence of osteogenic supple-
ments showed higher matrix mineralization, suggesting that
they were committed to the osteogenic lineage. On the other
hand, the non-bioactive (E-PA/K-PA) peptide nanofiber group
did not enhance differentiation into the osteogenic lineage.
These results are consistent with our previous studies, in
which GAG-mimetic peptide nanofibers were more effective
in inducing osteogenic differentiation compared to the
E-PA/K-PA group.20
In addition, ALP activity was considerably higher in the
GAG-PA treated group compared to non-bioactive controls, and
rMSCs undergoing differentiation on the GAG-PA nanofibers
have revealed significant differences in the osteogenic gene
expression profiles when compared to the E-PA group (Fig. 5),
suggesting that the GAG-mimetic nanofiber scaffold had
altered the differentiation pattern of the stem cells. This may
be due to their ability to recruit growth factors such as BMP to
increase the mRNA levels of downstream marker genes.47 In
addition, GAGs may facilitate osteoblast differentiation
through Erk phosphorylation and Runx2 activity.
After testing our system in vitro, we checked the regener-
ation ability of GAG-mimetic peptide nanofibers using a rabbit
tibial defect model. Fracture healing is a regenerative process
consisting of several phases, each involving the formation of a
different type of tissue.43 In the first phase, the inflammatory
response facilitates the formation of a hematoma and
granulation tissue. The second phase is characterized by the
formation of a soft callus that consists of cartilaginous or
chondroid tissue, while the third phase involves the ossifica-
tion of the soft callus to form a hard or bony callus consisting
primarily of woven bone tissue. Lastly, the final stage
comprises a remodeling phase, in which the woven bone is
gradually replaced by lamellar bone tissue. Although these
four phases are temporally sequential, the healing process is
not spatially uniform. Therefore, at any given time during
healing, the fracture callus is composed of a highly hetero-
geneous mixture of tissues.48 The regenerated tissue in
GAG-PA gel-treated bone defects was predominated by cortical
bone and had a greater mineral density compared to the physio-
logical saline treated sham group, as shown by Micro-CT
studies. It is therefore likely that the bioactive peptide matrix
is able to increase the rate of bone mineralization and matu-
ration. The rapid maturation rate of GAG-PA gel-treated tibial
bone defects may be attributed to the ability of GAG-mimetic
peptide nanofibers to enhance osteogenic differentiation, as
our in vitro studies suggest that GAG-mimetic peptide nano-
fibers induce significantly higher calcium deposition, osteo-
genic marker gene expression and ALP activity in rMSCs. As
Micro-CT analysis of bone tissue does not give full insight into
cellular composition dynamics and the biochemical character-
istics of newly formed bone, histological stainings were also
performed to further characterize the repair process. Physio-
logical saline-treated defects were mostly repaired with woven
bone tissue, with small amounts of lamellar bone, as bone
exhibits the capacity for self-renewal.40 On the other hand,
GAG-PA gel treated defects were filled with a more compact
form of bone, which indicates that the latter steps of bone
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healing had taken place in bioactive gel-treated tibiae. In
addition, Image J analysis of H&E staining results suggests
that the defect gap is bridged to a greater extent in GAG-PA
gel-treated gels (Fig. 8G), which supports our Micro-CT results
(Fig. 6A). High growth factor (VEGF, BMPs, FGF-1 and TGF-β)
binding capacity of the GAG-mimetic peptide nanofibers is a
potential factor contributing to the efficacy of the GAG-PA gel
treatment.19,20,49,50 The growth factor and nanofiber inter-
action facilitates migration and invasion of multipotent MSCs
originating from the periosteum, bone marrow, circulation,
and the surrounding soft tissue.19,20,43 Thus, the enhanced
growth factor binding ability and the nanofibrous morphology
of the GAG-PA system are likely to be the cause of enhanced
bone regeneration in the GAG-PA group compared to sham
treatment.
Previously, Sawyer et al. showed bone healing within a rat
calvarial defect by using poly ε-caprolactone/tricalcium phos-
phate (mPCL–TCP) scaffolds with recombinant human (rh)
BMP-2. Semi-quantitative measurements of the traverse sec-
tions demonstrated 30.6% ± 4.2 bone healing at 4 weeks.51
Hao et al. showed that rabbit radial defects were implanted
with a combination of rabbit adipose-derived stem cells encap-
sulated in collagen I gel with PLGA-β-TCP. After 8 weeks, the
bone forming area was 44.2 ± 3.9%. After 16 weeks, the newly
formed bone occupied 75.3 ± 2.6% of the total area and
increased to 96.4 ± 2.3% eight weeks later.52 Our model was
able to induce 54% recovery within four weeks in a smaller
defect; however, it should be noted that the present scaffold is
cell-free and growth factor-free. Therefore, inclusion of cells
and growth factors may further improve the success of the
GAG-mimetic nanofiber system, which exhibits a high affinity
for BMP-2 in particular. Further studies involving growth
factor and cell encapsulation methods are therefore necessary
to determine the full therapeutic potential of the present
system.
5. Conclusion
In summary, we have demonstrated that the GAG-mimetic
peptide nanofiber system is able to provide a biocompatible
and bioactive environment for promotion of osteogenic differ-
entiation of stem cells. The rMSCs cultured on these peptide
nanofibers exhibited enhanced alkaline phosphatase activity,
calcium deposition, and osteogenic gene expression, which are
the main indicators of bone-like mineralization. In addition,
in vivo bone regeneration studies using this PA gel system
demonstrated that GAG-PA gel treatment is associated with a
rapid maturation rate, higher cortical bone formation and
mineralization compared to the saline sham group. Therefore,
the GAG-mimetic PA nanofiber gel is a promising candidate
for the osteogenic differentiation of MSCs, and further studies
regarding the in vivo efficiency of the PA nanofiber system may
allow its use as an injectable scaffold to support the repair of
bone defects in orthopedic applications.
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